Published in Arch Dermatol Res on June 15, 2004
INTS6/DICE1 inhibits growth of human androgen-independent prostate cancer cells by altering the cell cycle profile and Wnt signaling. Cancer Cell Int (2009) 0.84
The FBI1/Akirin2 target gene, BCAM, acts as a suppressive oncogene. PLoS One (2013) 0.77
Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat Biotechnol (2006) 4.71
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood (2005) 2.55
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood (2009) 2.50
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood (2010) 2.34
Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol (2008) 2.32
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol (2009) 2.28
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol (2009) 2.02
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Managing comorbid disease in patients with psoriasis. BMJ (2010) 1.89
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res (2006) 1.86
Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med (2002) 1.75
KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst (2008) 1.72
Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol (2004) 1.70
Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood (2010) 1.67
MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol (2011) 1.67
The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One (2008) 1.60
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol (2007) 1.59
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta Oncol (2006) 1.48
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol (2006) 1.48
Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. Cell Host Microbe (2012) 1.45
Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol (2010) 1.43
[Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501): practical experiences in problem-patients with actinic keratoses and basal cell carcinomas]. J Dtsch Dermatol Ges (2004) 1.38
Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol (2010) 1.34
Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J (2012) 1.31
Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology (2002) 1.31
Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood (2008) 1.28
Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol (2010) 1.28
Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol (2014) 1.27
Impaired adenosine-5'-triphosphate release from red blood cells promotes their adhesion to endothelial cells: a mechanism of hypoxemia after transfusion. Crit Care Med (2011) 1.26
Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst (2003) 1.25
Quantitative microscopy and nanoscopy of sickle red blood cells performed by wide field digital interferometry. J Biomed Opt (2011) 1.23
Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex. J Biol Chem (2011) 1.19
Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood (2007) 1.19
Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood (2002) 1.18
Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood (2004) 1.17
Clinical and genetic aspects of craniofrontonasal syndrome: towards resolving a genetic paradox. Mol Genet Metab (2005) 1.14
A role for caspase-1 in heart failure. Circ Res (2007) 1.13
Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. Blood (2009) 1.13
Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol (2007) 1.13
8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol (2010) 1.13
Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood (2012) 1.12
Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts. Eur Heart J (2012) 1.10
Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J Invest Dermatol (2005) 1.10
The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem (2007) 1.09
Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion (2008) 1.06
P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets (2007) 1.06
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol (2006) 1.06
Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood (2008) 1.05
A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. PLoS One (2012) 1.04
Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood (2011) 1.00
Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes. Am J Hematol (2011) 1.00
Surgical and obstetric outcomes in adults with sickle cell disease. Am J Med (2008) 1.00
Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch Dermatol (2010) 0.99
Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One (2013) 0.99
Update in retinoid therapy of acne. Dermatol Ther (2006) 0.98
Transfusion management in sickle cell disease. Hematol Oncol Clin North Am (2005) 0.98
The prevalence of common acquired melanocytic nevi and the relationship with skin type characteristics and sun exposure among children in Lithuania. Arch Dermatol (2005) 0.97
Reliability of diagnosis of melanoma in situ. Lancet (2002) 0.96
Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa. J Am Acad Dermatol (2005) 0.96
IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials (2013) 0.96
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. J Invest Dermatol (2009) 0.95
Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. Exp Dermatol (2004) 0.95
Dendritic epidermal T cells (DETC) are diminished in integrin alphaE(CD103)-deficient mice. J Invest Dermatol (2002) 0.94
[Current situation of dermatologic surgery in Germany]. J Dtsch Dermatol Ges (2006) 0.94
Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci U S A (2013) 0.94
Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. Haematologica (2008) 0.94
Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU. Blood (2004) 0.93
Successful Nd:YAG laser therapy for hair removal in the oral cavity after plastic reconstruction using hairy donor sites. Dermatology (2013) 0.93
Red cell antigens as functional molecules and obstacles to transfusion. Hematology Am Soc Hematol Educ Program (2002) 0.93
The impact of CFNS-causing EFNB1 mutations on ephrin-B1 function. BMC Med Genet (2010) 0.93
The Lutheran glycoprotein: a multifunctional adhesion receptor. Transfusion (2006) 0.93
Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro. Mol Immunol (2004) 0.93
Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice. Am J Pathol (2011) 0.92
Melanoma arising in segmental nevus spilus: detection by sequential digital dermatoscopy. J Am Acad Dermatol (2009) 0.92
Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol (2008) 0.91
The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases. Front Biosci (2008) 0.90
Integrin alpha E(CD103)beta 7 influences cellular shape and motility in a ligand-dependent fashion. Blood (2008) 0.90
Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol (2008) 0.90
Comparative in situ topoproteome analysis reveals differences in patch test-induced eczema: cytotoxicity-dominated nickel versus pleiotrope pollen reaction. Exp Dermatol (2009) 0.90
The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder. Arch Dermatol (2012) 0.89
Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. J Invest Dermatol (2009) 0.89
Cowpox infection transmitted from a domestic cat. J Dtsch Dermatol Ges (2008) 0.89